Skip to Content
Merck
CN
  • Vascular-promoting therapy reduced tumor growth and progression by improving chemotherapy efficacy.

Vascular-promoting therapy reduced tumor growth and progression by improving chemotherapy efficacy.

Cancer cell (2015-01-15)
Esther Bridges, Adrian L Harris
ABSTRACT

In this issue of Cancer Cell, Wong and colleagues describe a novel approach of increasing the number of functional blood vessels in tumors using a low-dose therapy regimen of Cilengtide and Verapamil. This method enhanced gemcitabine delivery, uptake, and metabolism within tumor cells to reduce tumor growth and progression.

MATERIALS
Product Number
Brand
Product Description

Supelco
(±)-Verapamil hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
(±)-Verapamil hydrochloride, ≥99% (titration), powder
Supelco
Verapamil hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
USP
Verapamil hydrochloride, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
2′-Deoxycytidine, ≥99% (HPLC)
Verapamil hydrochloride, European Pharmacopoeia (EP) Reference Standard